TEST:

MERCURY™

P=N/A; N=15000; Recruiting; Sponsor:Nanjing Shihejiyin Technology, Inc.

"Geneseeq Technology Inc. announced that Geneseeq’s multi-cancer minimal residual disease detection (MRD) and multi-cancer early detection (MCED) kits were both CE Marked for liquid biopsy use in solid tumor patients...The MRD detection kit (Shielding™) employs ultra-deep sequencing technology ATG-SEQ™ to detect low amounts of circulating tumor DNA (ctDNA) in the peripheral blood post-surgical intervention...For early cancer detection, the in vitro diagnostic kit uses highly sensitive next-generation sequencing-based technology MERCURY™ to assess multi-omics features of circulating free DNA (cfDNA) and detect tumorigenesis in health population."